BioMarin announced that its drug, Brineura (cerliponase alfa), received recommendation by NICE’s Highly Specialized Technology committee.
Pharma Analyst Kajal Jaddoo of GlobalData, a data and analytics company, offered her view on the potential the drug has. According to GlobalData, Brineura global sales are predicted to reach $358m by 2025.
“Brineura has the potential to be commercially successful as currently there is no cure or life-extending treatments for neuronal ceroid lipfuscinosis type 2 (CLN2), a rare inherited disease and GlobalData forecasts that Brineura will generate global sales of $358m by 2025.
“Though Brineura has received approval, it will still need to be evaluated by an ongoing judicial review and payers before it gains widespread use, meaning the drug may face a slow uptake.
“Brineura is a recombinant human tripeptidyl peptidase enzyme. It is administered by intracerebral route through patented technology. The drug was indicated to slow loss of movement ability in symptomatic pediatric patients aged three and older with infantile CLN2. Brineura is tripeptidyl Peptidase 1 (TPP1) replacement agent. It restores TPP1 enzyme activity and breaks down the storage materials that cause CLN2 disease.”
To read more about Brineura, you can read the comprehensive article we wrote on the drug here in May.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.